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Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially
and Geographically Diverse Population: the CHARGE-AF Consortium
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Background-—Tools for the prediction of atrial ﬁbrillation (AF) may identify high-risk individuals more likely to beneﬁt from
preventive interventions and serve as a benchmark to test novel putative risk factors.
Methods and Results-—Individual-level data from 3 large cohorts in the United States (Atherosclerosis Risk in Communities [ARIC]
study, the Cardiovascular Health Study [CHS], and the Framingham Heart Study [FHS]), including 18 556 men and women aged 46
to 94 years (19% African Americans, 81% whites) were pooled to derive predictive models for AF using clinical variables. Validation
of the derived models was performed in 7672 participants from the Age, Gene and Environment—Reykjavik study (AGES) and the
Rotterdam Study (RS). The analysis included 1186 incident AF cases in the derivation cohorts and 585 in the validation cohorts. A
simple 5-year predictive model including the variables age, race, height, weight, systolic and diastolic blood pressure, current
smoking, use of antihypertensive medication, diabetes, and history of myocardial infarction and heart failure had good
discrimination (C-statistic, 0.765; 95% CI, 0.748 to 0.781). Addition of variables from the electrocardiogram did not improve the
overall model discrimination (C-statistic, 0.767; 95% CI, 0.750 to 0.783; categorical net reclassiﬁcation improvement, 0.0032;
95% CI, 0.0178 to 0.0113). In the validation cohorts, discrimination was acceptable (AGES C-statistic, 0.664; 95% CI, 0.632 to
0.697 and RS C-statistic, 0.705; 95% CI, 0.664 to 0.747) and calibration was adequate.
Conclusion-—A risk model including variables readily available in primary care settings adequately predicted AF in diverse
populations from the United States and Europe. ( J Am Heart Assoc. 2013;2:e000102 doi: 10.1161/JAHA.112.000102)
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A trial ﬁbrillation (AF), a common cardiac arrhythmia, hasemerged as a major public health problem as a result of
wide prevalence,1 close relation to stroke and mortality,2 and
associated costs.3 Tools for the prediction of AF could help
identify high-risk individuals and serve as a benchmark to test
potential novel risk factors. To this end, the Framingham
Heart Study (FHS) developed a risk score for AF, which
included a number of variables easily obtained during routine
clinical examination.4 This risk score was recently validated in
2 additional population-based cohorts, the Age Gene/Envi-
ronment Susceptibility-Reykjavik (AGES) Study and the
Cardiovascular Health Study (CHS), where it demonstrated
reasonable performance.5 An alternative score has been
developed in the Atherosclerosis Risk in Communities (ARIC)
Study, with similar predictive capability.6 These studies
included atrial ﬂutter in their deﬁnition of AF. This inclusion
is reasonable because, even though atrial ﬂutter and AF are
electrophysiologically distinct, most patients with atrial ﬂutter
have or will develop AF and the risk of stroke associated with
atrial ﬂutter is similar to that observed in AF.7,8
Previous risk models are limited as a result of being
developed in single cohorts. Though the FHS risk score has
predicted AF reasonably well in other populations,5,6 it is
unknown whether a risk model developed in a more geograph-
ically or racially diverse population would better predict AF.
Previously developed models also require information from a
12-lead electrocardiogram, which might be unavailable in some
primary care settings. Therefore, we developed and validated a
new predictive score for AF (including atrial ﬂutter) in 5 US and
European cohorts participating in the Cohorts for Heart and
Aging Research in Genomic Epidemiology (CHARGE) AF
consortium.9
Methods
Study Cohorts
Participant-speciﬁc data from 3 community-based cohorts in
the United States (ARIC, CHS, and FHS) were pooled to
develop a risk score for predicting AF, and the validation of
this score was performed in 2 additional cohorts in Europe
(AGES and the Rotterdam Study [RS]). A brief description of
each participating cohort is provided below. For each cohort
the determination of which examination to select as baseline
was based on the availability of potential predictors and
adequate follow-up for the development of AF. Participants
were excluded from this analysis if they had AF at baseline,
were younger than 46 or older than 94 years of age, had
serum creatinine ≥2.0 mg/dL, identiﬁed themselves as other
than white or African American (n=30 ARIC, n=32 CHS, and
n=62 RS participants), or had missing values for any of the
variables of interest. After applying exclusion criteria, the
derivation cohort included 18 556 participants and the
validation cohorts included a total of 7672 participants. The
number of individuals excluded by cohort is provided in the
Table S1. Institutional Review Boards at the participating
institutions approved the individual studies and study partic-
ipants provided written informed consent.
Atherosclerosis Risk in Communities Study
The ARIC study recruited 15 792 men and women, aged 45 to
64 years, from 4 communities in the United States (Forsyth
County, NC; Washington County, MD; Jackson, MS; and
suburbs of Minneapolis, MN) in 1987–1989.10 Participants
were mostly white in the Minnesota and Washington County
ﬁeld centers, white and African American in Forsyth County,
and exclusively African American in the Jackson ﬁeld center.
After study inception, participants had 3 follow-up examina-
tions, each 3 years apart. For the present analysis, we
included individuals attending the last follow-up examination
(visit 4, conducted in 1996–1998, n=11 656), with this
examination used as baseline in all models. Of these, 10 675
met inclusion criteria.
Cardiovascular Health Study
In 1989–1990, CHS recruited 5201 men and women 65 years
or older from 4 communities (Forsyth County, NC; Washington
County, MD; Sacramento County, CA; and Pittsburgh, PA).
Because of the different age inclusion criteria there was no
overlap in ARIC and CHS participants. In 1992–1993, 687
African Americans were recruited in 3 of the 4 communities to
increase minority representation.11 CHS participants had
annual follow-up examinations through 1999 with ongoing
surveillance for cardiovascular events from baseline through
the present. The 1989–1990 examination was considered
baseline for 3768 (65%) of the eligible CHS participants in
this analysis, while 1992–1993 was the baseline examination
for the rest (n=1275).
Framingham Heart Study
In 1971–1975, the FHS Offspring cohort recruited 5124
predominantly white men and women, offspring (and their
spouses) from the Original FHS cohort with follow-up
examinations every 4 to 8 years.12 The current analysis
included participants of the FHS Offspring cohort free of AF
attending the 6th examination cycle (1995–1998, n=3113);
2838 met inclusion criteria and were included in the analysis.
Age, Gene/Environment Susceptibility Reykjavik Study
The original Reykjavik Study, conducted between 1967 and
1996, included 19 000 men and women living in the greater
Reykjavik area, born between 1907 and 1935.13 Survivors of
DOI: 10.1161/JAHA.112.000102 Journal of the American Heart Association 2
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this study were invited to be part of AGES, which recruited
5764 men and women in 2002–2006. Of these, 5427 had a
complete clinic exam, and 4469 met inclusion criteria and
were considered for this analysis.
Rotterdam Study
The RS, a prospective population-based study aimed to assess
the determinants of chronic conditions in the elderly,
examined 7983 men and women, aged 55 years and older,
living in the Rotterdam suburb of Ommoord in 1989–1993.14
Since then, participants have been continuously followed and
were reexamined in 1993–1994, 1997–1999, 2002–2004
and 2008–2010. The present analysis included 3203 study
participants examined in 1997–1999 meeting inclusion
criteria.
Ascertainment of Incident AF
Incident AF cases in all 5 studies were ascertained from study
electrocardiograms and hospitalization discharge diagnosis
codes (ICD9-CM 427.3, 427.31 or 427.32, or ICD10 I48 in
any position).15–18 Individuals with atrial ﬂutter were included
as AF cases. AF ascertainment in FHS required additional
adjudication of cases by study cardiologists using electrocar-
diographic and clinical data from the FHS clinic, outside
hospital, or general practitioner records.17 Cases included in
the present analysis occurred between 2002–2011 in AGES,
1996–2005 in ARIC, 1989–2000 in CHS, 1995–2005 in FHS,
and 1997–2005 in RS. Further details of AF ascertainment are
available in the online supplementary materials.
Other Measurements
In all 5 study cohorts, examinations included a 12-lead
electrocardiogram, standardized measurements of anthro-
pometry, blood pressures, blood lipids, and fasting glucose, as
well as assessment of prior cardiovascular disease and
medication use.10–13,19 Details on measurement methods are
provided in the online supplementary materials. Protocols for
variable ascertainment and deﬁnitions of cardiovascular risk
factors were comparable across cohorts.
Statistical Analysis
Derivation of the predictive model
Means and standard deviation and frequency distribution of
relevant covariates were calculated by cohort and race. We
initially ran cohort- and race-speciﬁc Cox proportional hazard
models to assess individual predictors of AF after age- and
sex-adjustment in each cohort up to 7 years of follow-up.
Variables considered included age, sex, height, weight,
current smoking, systolic and diastolic blood pressure, use
of antihypertensive medication, history of diabetes, fasting
blood glucose, estimated glomerular ﬁltration rate (eGFR)
<60 mL/kg per m2,20 total blood cholesterol, HDL choles-
terol, triglycerides, heart rate, electrocardiographic-derived
left ventricular hypertrophy, PR interval, history of coronary
artery bypass graft (CABG), history of heart failure, history of
myocardial infarction, and history of stroke. We selected as
candidate predictors for our pooled model any variable
signiﬁcantly associated with AF (P<0.05) in at least 2 of the
3 cohorts, and ran the ﬁnal Cox proportional hazards model
on our participant-speciﬁc pooled data using backward
selection of variables (P<0.05 to remain in the model). Age,
sex, and race interactions were tested, as was the assumption
of proportional hazards. Model-based individual 5-year risk of
AF was calculated. We evaluated model performance using
the C-statistic,21 discrimination slopes,22 and Nam and
D’Agostino’s modiﬁed Hosmer-Lemeshow chi-square statistic
for survival analysis.23
To facilitate the use of our score in those clinical settings
with limited access to electrocardiograms or blood tests, we
ﬁrst developed a predictive model that did not require
information from electrocardiogram and blood tests (which
we labeled “simple model”). We then developed a more
complex model adding electrocardiographic variables and
blood tests (labeled “augmented model”). Variables were
retained in the models if they were signiﬁcantly associated
with AF incidence (P<0.05). We calculated the added
predicted value of the augmented model versus the simple
model with the increment in the C-statistic and the categor-
ical net reclassiﬁcation improvement (NRI) using the following
risk categories: <2.5%, 2.5% to 5%, >5%.22
Validation analysis
The models developed in the derivation cohorts were applied
in AGES and the RS to estimate the 5-year risk of developing
AF. As in the derivation analysis, model performance was
assessed using the C statistic, discrimination slopes, and Nam
and D’Agostino’s chi-square statistic metrics. To improve
adjustment ﬁt in the validation cohorts, we accounted for the
baseline survival of the respective cohort and the corre-
sponding risk factor means.24
Additional analyses
We compared the performance of the newly developed risk
score with the previous FHS AF risk score.4 To this end, we
calculated model quality measures in the pooled data from
ARIC, CHS, and FHS, and separately in AGES and RS after
applying the AF risk function previously derived from FHS.4
Because the presence of cardiac murmur, one of the variables
included in the FHS AF risk score, was not available in AGES
DOI: 10.1161/JAHA.112.000102 Journal of the American Heart Association 3
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and RS, and given its low prevalence (<3% in the FHS cohort),4
we assumed it to be absent for all participants in whom it was
not ascertained. Finally, we compared calibration and dis-
crimination of the derived risk model and the model
independently derived including those same variables in each
validation cohort. SAS-Software version 9.1 was used for all
analyses.
Results
Baseline characteristics of eligible individuals by cohort and
race (in ARIC and CHS) are presented in Table 1. The average
age in years ranged from 60 in FHS to 76 in AGES, and the
proportion of women was between 55% and 66% across
cohorts. African Americans comprised 19% of the derivation
sample. The prevalence of cardiovascular risk factors was
generally higher in African Americans than in whites. The
analysis included 1186 incident AF cases among 18 556
participants in the derivation cohorts, and 585 cases among
the 7672 participants in the validation cohorts.
A number of sociodemographic variables and cardiovas-
cular risk factors were consistently associated with age- and
sex-adjusted AF incidence across cohorts (Table 2). We
observed a higher risk of incident AF in men, older
individuals, those with higher height, weight, blood pressure,
and blood glucose, individuals with lower total cholesterol,
with electrocardiographic left ventricular hypertrophy, who
use hypertension medication, with diabetes, who are current
smokers, and with a previous history of heart failure or
myocardial infarction. Alcohol intake was not signiﬁcantly
Table 1. Baseline Characteristics in Derivation Cohorts and Validation Cohorts
Discovery Cohorts Validation Cohorts
FHS CHS whites CHS AA ARIC whites ARIC AA AGES RS
N 2838 4324 719 8305 2370 4469 3203
AF cases 143 560 64 343 76 408 177
Age, y 60 (8) 73 (5) 73 (5) 63 (6) 62 (6) 76 (6) 72 (7)
Sex, % female 54.5 58.8 65.9 54.5 64.4 60.4 58.9
Height, cm
Women 161 (6) 159 (6) 160 (6) 161 (6) 163 (6) 161 (6) 161(6)
Men 175 (7) 173 (7) 174 (7) 175 (7) 176 (7) 175 (6) 174(7)
Weight, kg 78.3 (17.1) 71.7 (14.3) 77.5 (15.6) 79.7 (16.9) 85.7 (18.2) 75.3 (14.5) 74.4 (12.3)
Current smoker, % 14.6 9.0 14.5 14.6 17.5 12.2 15.6
Systolic blood pressure, mm Hg 130 (19) 136 (21) 142 (22) 126 (18) 134 (20) 142 (21) 143 (21)
Diastolic blood pressure, mm Hg 76 (9) 70 (11) 76 (11) 70 (10) 76 (11) 74 (10) 75 (11)
Antihypertensive medication use, % 29.6 43.8 61.5 29.6 58.4 61.2 37.1
Diabetes, % 10.2 15.0 24.3 10.2 25.9 11.5 10.2
Fasting blood glucose, mg/dL 104 (28) 109 (33) 119 (55) 107 (31) 123 (56) 104 (21) 107 (27)
eGFR <60 mL/kg per m2, % 9.1 21.1 25.2 9.1 14.8 28.8 13.4
Total cholesterol, mg/dL 207 (38) 212 (38) 210 (38) 202 (36) 200 (38) 219 (44) 225 (38)
HDL cholesterol, mg/dL 51 (16) 54 (16) 58 (15) 49 (16) 53 (17) 62 (17) 54 (15)
Triglycerides, mg/dL 140 (95) 146 (82) 116 (65) 151 (90) 115 (63) 106 (57) 135 (66)
Heart rate, bpm 64 (10) 65 (11) 67 (14) 62 (10) 65 (11) 66 (11) 68 (11)
Electrocardiogram-derived LVH, % 0.7 3.5 9.0 0.7 4.8 — 5.0
PR interval, ms 164 (24) 170 (31) 172 (34) 166 (27) 171 (27) 173 (30) 170 (26)
CABG history, % 1.6 4.4 2.8 1.6 1.7 5.9 4.0
Prevalent heart failure, % 0.6 3.6 4.7 3.9 7.2 1.7 3.5
Prevalent myocardial infarction, % 4.0 9.4 8.2 4.0 4.6 7.0 10.8
Stroke history, % 0.5 3.3 5.8 0.5 3.6 6.0 3.7
Values correspond to percent or mean (standard deviation). FHS indicates Framingham Heart Study; CHS, Cardiovascular Health Study; AA, African Americans; ARIC, Atherosclerosis Risk
in Communities; AGES, Age, Gene and Environment Reykjavik Study; RS, Rotterdam Study; AF, atrial ﬁbrillation; eGFR, estimated glomerular ﬁltration rate; HDL, high-density lipoprotein;
LVH, left ventricular hypertrophy; CABG, coronary artery bypass graft surgery
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associated with AF risk in any of the derivation cohorts (data
not shown).
Derivation of the Predictive Model
Using a backward-selection algorithm in pooled data from
ARIC, CHS and FHS, the following variables were included in
the simple risk prediction score: age, race, height, weight,
systolic blood pressure, diastolic blood pressure, current
smoking, use of antihypertensive medication, diabetes, history
of myocardial infarction, and history of heart failure. In addition
to these variables, the PR interval and electrocardiogram-
derived left ventricular hypertrophy were selected to be
included in the augmented prediction score. The augmented
score did not select variables requiring measurement of lipid
levels, blood glucose, or creatinine. No signiﬁcant interactions
with age, sex, or race were observed. Table 3 includes the beta
coefﬁcients, standard errors, and hazard ratios with their 95%
CIs corresponding to the ﬁnal simple and augmented predic-
tive models. The simple predictive model achieved good
performance (C-statistic, 0.765; 95% CI, 0.748 to 0.781).
The addition of information from the electrocardiogram
provided no gain in predictive ability (C-statistic, 0.767; 95%
CI, 0.750 to 0.783). Inclusion of pulse pressure instead of
systolic and diastolic blood pressure, or of body mass index or
waist circumference instead of weight provided similar results
(data not shown). Similarly, the categorical NRI showed that
the addition of electrocardiographic variables did not improve
the predictive ability of the model (NRI, 0.0032; 95% CI,
0.0178 to 0.0113; Table S2).
The distribution of predicted 5-year risk of AF in the
derivation cohorts is provided in Figure 1 and the observed
cumulative risk of AF by predicted risk based on the simple
model is presented in Figure S1, separately for whites and
African Americans. An Excel spreadsheet (available as a
supplemental ﬁle) allows calculation of AF risk using this
predictive model.
Calibration of both models was adequate in the entire
derivation sample (Table 4, Figure 2) and individually in each
derivation cohort (Table S3). Discrimination using the previ-
ously developed FHS AF risk score (C-statistic, 0.734; 95% CI,
0.717 to 0.750) was lower than with the CHARGE score.
Validation of the Predictive Model
The model developed in ARIC, CHS and FHS, was validated in
2 European cohorts, AGES and RS. Table 4 reports discrim-
ination and calibration of the CHARGE-AF predictive models
in the validation cohorts. C-statistic values were 0.664 in
AGES and 0.705 in RS for the simple model, with similar
results for the augmented model. Calibration of the predictive
model after recalibration of the model using the average risk
Table 3. Final Multivariable Model for 5-year Risk of AF Derived in ARIC, CHS, and FHS*
Variable
Simple Model Augmented Model
Estimated b (SE) HR (95% CI) Estimated b (SE) HR (95% CI)
Age (5 years) 0.508 (0.022) 1.66 (1.59, 1.74) 0.501 (0.022) 1.65 (1.58, 1.72)
Race (white) 0.465 (0.093) 1.59 (1.33, 1.91) 0.486 (0.094) 1.63 (1.35, 1.95)
Height (10 cm) 0.248 (0.036) 1.28 (1.19, 1.38) 0.243 (0.037) 1.28 (1.19, 1.37)
Weight (15 kg) 0.115 (0.033) 1.12 (1.05, 1.20) 0.121 (0.033) 1.13 (1.06, 1.20)
Systolic BP (20 mm Hg) 0.197 (0.033) 1.22 (1.14, 1.30) 0.186 (0.033) 1.20 (1.13, 1.29)
Diastolic BP (10 mm Hg) 0.101 (0.032) 0.90 (0.85, 0.96) 0.098 (0.032) 0.91 (0.85, 0.97)
Smoking (current) 0.359 (0.091) 1.43 (1.20, 1.71) 0.365 (0.091) 1.44 (1.20, 1.72)
Antihypertensive medication use (Yes) 0.349 (0.063) 1.42 (1.25, 1.60) 0.341 (0.063) 1.41 (1.24, 1.59)
Diabetes (Yes) 0.237 (0.073) 1.27 (1.10, 1.46) 0.242 (0.073) 1.27 (1.10, 1.47)
Heart failure (Yes) 0.701 (0.106) 2.02 (1.64, 2.48) 0.678 (0.107) 1.97 (1.60, 2.43)
Myocardial infarction (Yes) 0.496 (0.089) 1.64 (1.38, 1.96) 0.469 (0.090) 1.60 (1.34, 1.91)
LVH by electrocardiogram (Yes) — — 0.401 (0.129) 1.49 (1.16, 1.92)
PR Interval (<120 vs 120 to 199) — — 0.645 (0.200) 1.91 (1.29, 2.82)
PR Interval (>199 vs 120 to 199) — — 0.118 (0.077) 1.13 (0.97, 1.31)
AF indicates atrial ﬁbrillation; ARIC, Atherosclerosis Risk in Communities; CHS, Cardiovascular Health Study; FHS, Framingham Heart Study; SE, standard error; HR, hazard ratio; CI,
conﬁdence interval; BP, Blood pressure; LVH, Left ventricular hypertrophy.
*All risk factors are classiﬁed at baseline examination. The 5-year risk for the simple model can be calculated as 10.9718412736exp(ΣbX 12.5815600) where b is the regression coefﬁcient
and X is the level for each risk factor; the risk for the augmented model is given as 10.9719033184exp(ΣbX 12.4411305). When calculating the 5-year risk, estimated b for age, height,
weight, systolic and diastolic blood pressure must be divided by the number of presented units.
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in each cohort was adequate in AGES and in RS (Table 4,
Figure 2).
In RS, the new CHARGE score performed slightly better
than the previous FHS risk score (C-statistic 0.705 for
CHARGE simple score versus 0.686 for FHS score), whereas
in AGES the CHARGE and FHS scores had similar discrimi-
nation (C-statistic 0.664 for CHARGE simple score versus
0.653 for FHS score).
Because of the relatively lower discrimination of the
predictive model in AGES, we calculated the C-statistic of a
Figure 1. Distribution of predicted 5-year risk of AF in the derivation cohorts by race using the Cohorts for Heart and Aging Research in
Genomic Epidemiology atrial ﬁbrillation (CHARGE-AF) simple score.
Table 4. Model Discrimination and Calibration by Cohort and Risk Score
Pooled ARIC, CHS and FHS AGES RS
N 18 556 4469 3203
CHARGE AF Simple Score
C-statistic (95% CI) 0.765 (0.748 to 0.781) 0.664 (0.632 to 0.697) 0.705 (0.663 to 0.747)
Calibration chi-square (P-value) 9.3 (0.41) 12.6 (0.18) 16.4 (0.06)
Discrimination slope 0.056 0.026 0.022
CHARGE AF Augmented Score
C-statistic (95% CI) 0.767 (0.750 to 0.783) 0.665 (0.633 to 0.697) 0.716 (0.680 to 0.761)
Calibration chi-square (P-value) 5.4 (0.80) 16.7 (0.053) 10.1 (0.34)
Discrimination slope 0.059 0.027 0.023
FHS AF Score*
C-statistic (95% CI) 0.734 (0.717 to 0.750) 0.652 (0.621 to 0.684) 0.686 (0.642 to 0.729)
Calibration chi-square (P-value) 26.5 (0.002) 12.2 (0.20) 8.5 (0.49)
Discrimination slope 0.050 0.025 0.017
Cohort’s Own Model
C-statistic (95% CI) — 0.668 (0.637 to 0.700) 0.733 (0.690 to 0.776)
Calibration chi-square (P-value) — 11.8 (0.23) 10.9 (0.28)
Discrimination slope — 0.025 0.026
ARIC indicates Atherosclerosis Risk in Communities; CHS, Cardiovascular Health Study; FHS indicates Framingham Heart Study; AGES, Age, Gene and Environment Reykjavik Study;
RS, Rotterdam Study; CHARGE AF, Cohorts for Heart and Aging Research in Genomic Epidemiology atrial ﬁbrillation; CI, conﬁdence interval.
*Discrimination and calibration of FHS AF score were obtained applying the published coefﬁcients and calibrated using overall risk.
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model independently derived in the validation cohorts includ-
ing the variables selected for the CHARGE risk model. Using
this approach, the C-statistic in AGES was 0.668 (95% CI,
0.637 to 0.700) and in RS was 0.733 (95% CI, 0.690 to
0.776), not very different from values obtained using the
CHARGE risk model (Table 4).
Discussion
In our individual-level pooled analysis of 3 large community-
based prospective studies in the United States, we found that
a simple risk model including variables routinely collected in a
primary care setting are useful to predict the future risk of AF.
Discrimination ability of the model was comparable or
superior to other risk stratiﬁcation schemes developed for
coronary heart disease or stroke.24–26 The predictive model
performed reasonably well in 2 additional cohorts in Europe
when compared to the cohorts’ own models. Including
variables obtained from a 12-lead electrocardiogram provided
no signiﬁcant additional predictive ability.
Previous models for the prediction of AF have been reported
already, but these were developed in single cohorts.4,6
Although the FHS AF risk score has shown acceptable
discrimination in populations other than the cohort in which
it was developed,5,6 important improvements of the CHARGE-
AF model were the availability of participant-speciﬁc data from
several cohorts and the larger sample size included in its
development and validation. The CHARGE-AF model utilized
more than 26 000 individuals with over 1750 AF cases. The
geographic and racial diversity of the participating cohorts
provided increased generalizability over and above the FHS AF
risk score alone. A further advantage of the CHARGE-AF
predictive model is that it does not require extra diagnostic
tests beyond what is usually available in primary care settings.
We also found that the CHARGE-AF model performed better
than the original FHS AF score in the derivation and validation
cohorts. However, lack of information on cardiac murmur in
ARIC, CHS, RS and AGES limits the value of the FHS AF score in
these cohorts. Similarly, we did not study discrimination of the
ARIC risk score in the CHARGE cohorts since the ARIC score
was derived in a middle-aged cohort (45 to 64 years old at
baseline), whereas most individuals in the present analysis
were older.
The CHARGE-AF predictive model shares some variables with
previously developed risk scores for coronary heart dis-
ease,24,25,27 heart failure,28,29 stroke,26 or general cardiovascular
risk.30 However, the weight of individual risk factors in these
other models differs from the CHARGE-AFmodel and their ability
to accurately predict AF has been shown inadequate.6
The CHARGE-AF predictive model could have important
research and clinical applications. The most immediate
application might be to serve as a standard in evaluating the
ability of putative novel clinical factors, biomarkers, subclinical
measures, or ‘-omic’ (eg, genomic, epigenomic, transcriptomic,
proteomic, metabolomic) tests to reclassify an individual’s risk
of developing AF. In addition, the predictive model might be
used to select high-risk individuals for trials of primary
prevention of AF or intensive monitoring for AF detection.
Our 5-year predictive model also may be useful once primary
prevention strategies are developed, to facilitate identiﬁcation
of individuals more likely to beneﬁt from them. Finally, given
the association of some cardiovascular risk factors, such as
hypertension, obesity, diabetes, or the metabolic syn-
drome,31–35 with the risk of AF, the CHARGE-AF predictive
model may, in the future, contribute to guidelines for selecting
candidates for more aggressive risk factor control. Future
randomized trials and observational studies should determine
if such approaches are useful and cost-effective.
In the proposed predictive model we found that higher
systolic blood pressure was associated with higher AF risk,
whereas diastolic blood pressure was inversely associated
with AF incidence. This observation is consistent with a
previous report from the FHS in which pulse pressure was a
better predictor of AF than systolic or diastolic blood pressure
alone.31 We chose to include systolic and diastolic blood
pressure as separate variables in our model, instead of pulse
0
0.05
0.1
0.15
0.2
1 2 3 4 5 6 7 8 9 10
Decile
African-Americans
Pred
Obs
0
0.05
0.1
0.15
0.2
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Figure 2. Calibration plots for the Cohorts for Heart and Aging
Research in Genomic Epidemiology atrial ﬁbrillation (CHARGE-AF)
simple score model in the combined derivation cohorts, by race. The
x-axis refers to deciles of predicted AF risk. Each bar in the graph
represents the average observed and predicted AF risk.
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pressure, because they are more commonly recorded in the
clinical setting. Including pulse pressure provided similar
results as those presented in the current analyses. Similarly,
we included weight in the models even though waist
circumference or body mass index, and not weight, may be
the pathophysiologically relevant factors. In the derivation
cohorts, however, models with waist circumference or body
mass index offered similar discrimination ability. Which of
these variables is more relevant from an etiopathogenic point
of view needs to be addressed in future work.
Several variables included in the CHARGE-AF predictive
model were part of both the published FHS and ARIC AF risk
scores, including age, systolic blood pressure, use of antihy-
pertensive medication, and history of heart failure (Table S4).
Other variables in the CHARGE-AF model, however, were part
of only one of the risk scores, such as race, smoking, height,
diabetes, or myocardial infarction (in ARIC), and body mass
index (in FHS). Similar to the ARIC model,6 sex was not
selected as a predictor in the CHARGE-AF model. Even though
AF incidence is higher in men than women, our model
suggests that sex differences in the distribution of AF
predictors may account for this disparity. In the initial
analysis, we observed an unexpected inverse association
between total cholesterol and AF risk. Upon further adjust-
ment, cholesterol levels did not show a signiﬁcant association
with AF. Of note, an inverse association between total and
LDL cholesterol was found in an analysis conducted in the
ARIC study.36
We observed that the model had lower discrimination
ability in AGES (C-statistic, 0.67). Discrimination only mini-
mally improved in a model derived speciﬁcally in AGES using
the CHARGE-AF variables (C-statistic, 0.68). In contrast,
discrimination of the CHARGE-AF model was better in RS
(C-statistic, 0.71). We can only speculate about the reasons
to explain these differences. AGES participants were, on
average, older than participants from other cohorts. Also,
cohort differences in the determination of AF or in the
impact of genetic risk factors may partly explain these
results.
Strengths and Limitations
Our work has limitations that must be acknowledged. We
restricted the age range of our risk score because very few
individuals were younger than 46 or older than 94 years. The
applicability of our risk model to individuals <46 or >94 years
and to individuals not of African or European ancestry is
uncertain. Our risk score will need to be validated outside the
United States and Western Europe and in other ethnicities (eg,
Asians and Hispanics). Similarly, since participants needed to
attend a baseline cohort examination in order to be included,
the generalizability of the risk score to hospitalized patients or
non-ambulatory settings is unknown. Most of the cohorts
relied on periodic clinic examinations and hospitalization ICD
codes leading to the potential for misclassiﬁcation of AF,
though validation studies in the ARIC study, CHS, and other
populations have shown adequate validity of this case
deﬁnition.15,16,37 We also have shown previously that age-
and race-speciﬁc incidence rates of AF in the derivation
cohorts were similar in spite of the differences in AF
ascertainment.16 In addition, we note that AF is not
infrequently asymptomatic or paroxysmal, being potentially
missed in our cohorts. We included initial, paroxysmal,
persistent, and permanent AF for which prediction may be
heterogeneous. We acknowledge being unable to accurately
comment on risk prediction for AF versus atrial ﬂutter. We
combined the 2 for several reasons including that they
frequently complicate each other’s course,7 they are reported
to have similar risk factors,8 and because ICD codes may not
accurately distinguish between them.38,39 Furthermore, we
did not account for measurement error in determining risk
factors. We pooled participant-level data assuming a priori
that the associations of risk factors with AF in the subjects
representing 3 large US cohort studies are sufﬁciently
homogeneous. Strengths of our analysis include the large
sample size, the number of AF cases included in the analysis,
the inclusion of multiple cohort studies—enhancing general-
izability, the availability of a large number of possible AF
predictors, the racial diversity in the studied samples, and
external replication.
In conclusion, we have developed a new risk model for the
prediction of AF. The proposed model has the advantage of
being simpler, using information readily available in a primary
care setting, and having been developed in a larger popula-
tion. Future research should determine whether biomarkers or
genetic factors have value in the prediction of AF beyond that
of clinical risk factors.
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SUPPLEMENTAL MATERIAL 
Online methods 
AF ascertainment 
AGES 
Atrial fibrillation or atrial flutter was diagnosed from Minnesota-coded ECGs recorded at AGES study 
exams and from ICD-9 427.3 or ICD-10 I48 codes from hospital discharges in the National Hospital of 
Iceland database through April 2010.  
ARIC 
AF in ARIC was identified from 3 sources: ECG conducted at each study visit, hospital discharge codes 
(ICD-9CM 427.31, AF, or 427.32, atrial flutter), and death certificates (ICD-9 427.3 or ICD-10 I48). AF 
cases occurring during the same hospitalization as open cardiac surgery were not included as events.1, 2 
CHS 
Incidence of AF and atrial flutter in CHS was identified from standard 12-lead electrocardiograms 
performed at each study visit, and from hospitalization discharge codes (ICD-9CM 427.31 or 427.32). 
Data from hospitalizations have been obtained through biannual contact with study participants and 
from information obtained from the Centers for Medicare and Medicaid Services.3 
FHS 
Participants were classified as having AF if atrial fibrillation or atrial flutter was present on an ECG 
derived from a Framingham Study clinic tracing, on an ECG during an encounter with an external 
clinician, or by Holter monitoring, or if it was noted in hospital records. All incident AF cases were 
reviewed and adjudicated by one of two Framingham cardiologists.4 
RS 
AF cases were ascertained at baseline and during follow-up as described previously.5 Briefly, ECGs were 
recorded and stored digitally, and analyzed by the Modular ECG Analysis System. Two research 
physicians and a cardiologist verified AF diagnoses. Additional information was obtained from general 
practitioner records, from outpatient clinics, and from a national database of hospitalizations, which 
records all hospitalization discharge diagnoses occurring in the Netherlands. AF cases occurring during a 
serious disease resulting in death, or during myocardial infarction or cardiac operative procedures who 
recovered during the hospital admission were not included. 
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Assessment of covariates 
AGES 
Standard examination protocols and questionnaires were completed in the AGES study. Clinic visits 
included anthropometry, blood pressure measurement (defined as the mean value of two consecutive 
blood pressure measurements), electrocardiogram, and measures of different physical and cognitive 
function domains. Blood samples were drawn after overnight fasting. Total cholesterol, high-density 
lipoprotein (HDL) cholesterol, triglycerides, and glucose were analyzed on a Hitachi 912, using reagents 
from Roche Diagnostics and following the manufacturer's instructions. Low-density lipoprotein (LDL) 
was calculated using the Friedewald equation. Diabetes was defined from a self-report of a physician 
diagnosis, use of oral hypoglycemic agents or insulin, or a fasting blood glucose ≥126 mg/dL. Diagnoses 
of myocardial infarction and heart failure were based on hospital discharge records. 
ARIC 
Study participants were asked to fast for 12 hours before the clinic visit, during which a blood sample 
was obtained and a physical examination performed.  Race, smoking status, and drinking status were 
determined by participant self-report. Blood collection and processing techniques for the ARIC study 
have been previously described.6 Enzymatic methods were used to measure total cholesterol and 
triglycerides. High-density lipoprotein cholesterol was measured enzymatically after dextran sulfate-
Mg2+ precipitation of other lipoproteins. Low-density lipoprotein cholesterol levels were estimated using 
the Friedewald formula for subjects with triglycerides levels <400 mg/dl.  Standing height and waist 
circumference (at the level of the umbilicus) were measured to the nearest centimeter in a scrub suit 
and without shoes. Body mass index was calculated as weight (in kilograms) divided by height (in 
meters) squared. Blood pressure was measured 3 times with the subject in the sitting position after 5 
minutes of rest using a random-zero sphygmomanometer, and the last 2 measurements were averaged. 
Participants were asked to bring all medications with them to the clinic visits. A prescription bottle or 
self-report was used to determine cholesterol and blood pressure medication use. A 12-lead ECG at rest 
was used to define the PR interval and the presence of left ventricular hypertrophy (LVH). ECG-
diagnosed LVH was considered present if the Cornell voltage was >28 mm in men or >22 mm in women. 
A participant was categorized as having diabetes if she or he had a fasting glucose of ≥126 mg/dl or 
nonfasting glucose level of ≥200 mg/dl, reported a physician diagnosis of diabetes, or was currently 
taking medication for diabetes. Prevalent coronary heart disease at baseline included a history of 
myocardial infarction, myocardial infarction adjudicated from the baseline ECG, or a history of coronary 
bypass or angioplasty. Prevalent heart failure was defined as a previous hospitalization for heart failure. 
Presence of cardiac murmur was assessed in the baseline examination but not in following visits. 
CHS 
Participants had annual examinations including assessment of cardiovascular risk factors, prior 
cardiovascular diseases, medications, height, weight, seated blood pressure, and a 12-lead 
electrocardiogram through 1999. Racial identity was provided by self-report. A history of heart failure at 
baseline was defined by signs, symptoms, clinical tests, physician diagnosis, and/or medical therapy. 
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Prevalent coronary heart disease was defined by a history of myocardial infarction or angina pectoris 
confirmed by retrospective review of hospitalization medical records, or self-report of coronary 
angioplasty. Diabetes was defined as use of oral hypoglycemic agents or insulin, or a fasting blood 
glucose ≥126 mg/dl. ECG-LVH was defined according to Cornell voltage. 
FHS 
Cardiovascular disease risk factors were defined as follows: diabetes was diagnosed as fasting glucose 
≥126 mg/dL, or use of hypoglycemic medications; the average of two Framingham Study physician 
systolic and diastolic blood pressure measurements in mm Hg with the participant seated. Medication, 
alcohol use and smoking were ascertained by self-report. Current smoking was defined as regular use of 
one or more cigarettes/day within the year prior to the Framingham clinic visit. Glucose and lipids were 
measured after an overnight fast in the Framingham Study laboratory. Cardiovascular events were 
adjudicated by a panel of 3 physicians, examining participant hospitalization and outpatient records. 
Heart failure was diagnosed based on major and minor clinical criteria that have been used for all heart 
failure cases of Framingham Heart Study participants. Myocardial infarction was diagnosed based on the 
presence of clinical history, electrocardiographic signs, and biomarkers. ECG-based left ventricular 
hypertrophy was considered present when a participant had voltage criteria for left ventricular 
hypertrophy with lateral repolarization changes.7 
RS 
Information on current health status, medical history, and smoking was obtained using a computerized 
questionnaire. Participants were classified as current or non-smokers. Body mass index (BMI) was 
calculated as weight in kilograms divided by the square of height in meters. Blood pressure was 
measured twice at the right upper arm with a random zero mercury sphygmomanometer in the sitting 
position. Systolic and diastolic blood pressures were calculated as the average of the two consecutive 
measurements. A history of myocardial infarction was defined as a self-reported myocardial infarction 
with hospital admission or the presence of a myocardial infarction on the ECG. Left ventricular 
hypertrophy was diagnosed by the MEANS program using the Sokolow-Lyon cut-off of ≥3500 V. 
Diabetes was defined as the use of anti-diabetic medication or a random or post-load serum glucose 
level of 200 mg/dL or more. Diagnosis of heart failure was based on a score of heart failure symptoms, 
on medication prescribed with the indication of heart failure, on hospital discharge diagnoses, and on 
the information available in general practitioner files. Blood samples were drawn by venipuncture, and 
serum total cholesterol and HDL cholesterol were measured with an automated enzymatic method. 
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eTable 1. Number of participants excluded by cohort applying exclusion criteria sequentially 
 ARIC CHS FHS AGES RS 
Initial sample 11656 5353 3113 5427* 4215 
Prevalent AF 521 150 PE 527 282 
Age <46 or >94, years 0 7 275 5 21 
Creatinine ≥2 mg/dL 48 84 PE 55 8 
Not white or African-American 30 32 0 0 62 
Missing variables 382 37 PE 371 639 
Eligible sample 10675 5043 2838 4469 3203 
PE: Previously excluded from study sample 
 
* There are 5764 participants in the AGES cohort, but only 5427 came to the study center. Other 
participants received a home-visit or provided blood samples only and, therefore, were excluded from 
this analysis. 
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eTable 2. Reclassification among individuals who developed AF and who did not develop AF during a 5-
year follow-up using the augmented score (which includes ECG measurements). Net reclassification 
improvement (NRI), -0.0032; 95% CI, -0.0178 to 0.0113. 
 
Participants who developed AF 
Augmented score 
Simple score <2.5% 2.5-5% >5% Total 
<2.5% 97 6 1 104 
2.5-5% 4 161 5 171 
>5% 0 16 517 532 
Total 101 183 523 807 
Participants who did not develop AF 
Augmented score 
Simple score <2.5% 2.5-5% >5% Total 
<2.5% 8109 151 0 8260 
2.5-5% 192 4499 184 4875 
>5% 0 248 4366 4614 
Total 8301 4898 4550 17749 
Data are number of participants. Green cells correspond to desirable reclassification, while red cells 
correspond to undesirable reclassification. 
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eTable 3. Model discrimination and calibration separately in each derivation cohort 
 ARIC CHS FHS 
N 10675 5042 2831 
CHARGE AF simple score 
C-statistic (95% CI)  0.71 (0.68, 0.74)  0.70 (0.68, 0.73)  0.78 (0.74, 0.83) 
Calibration chi-square (p-value)  6.6 (0.67)  17.3 (0.045)  14.2 (0.11) 
Discrimination slope 0.017 0.054  0.057 
CHARGE AF augmented score 
C-statistic (95% CI)  0.72 (0.68, 0.75) 0.71 (0.68, 0.73)   0.78 (0.74, 0.83) 
Calibration chi-square (p-value) 5.1 (0.82) 11.1 (0.27)   8.0 (0.54) 
Discrimination slope 0.018  0.058 0.060 
FHS AF score 
C-statistic (95% CI)  0.67 (0.64, 0.71) 0.66 (0.64, 0.69)   0.78 (0.74, 0.82) 
Calibration chi-square, p-value  32.2 (0.0002)  279.8 (<0.0001)  45.1 (<0.0001) 
Discrimination slope  0.013  0.046  0.049 
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eTable 4. Variables included in the CHARGE-AF simple model and previously published risk models for 
the prediction of AF 
CHARGE-AF FHS risk score8 ARIC risk score9 
age age age 
 sex  
race  race 
height  height 
weight body mass index  
systolic BP systolic BP systolic BP 
diastolic BP   
smoking  smoking 
antihypertensive medication antihypertensive medication antihypertensive medication 
diabetes   
myocardial infarction  coronary heart disease 
heart failure heart failure heart failure 
 cardiac murmur cardiac murmur 
 PR interval  
  ECG-derived LVH 
  ECG-derived LAE 
BP: blood pressure; ECG: electrocardiogram; LAE: left atrial enlargement; LVH: left ventricular 
hypertrophy 
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eFigure 1. Observed cumulative risk of AF by categories of predicted risk according to CHARGE AF simple 
score in whites and African Americans. Green line: >5%, red line: 2.5-5%, blue line: <2.5%
 
Year 0 1 2 3 4 5 
5-year 
predicted risk 
Persons at risk by year 
<2.5% 6547 6516 6489 6440 6379 6305 
2.5-5% 4297 4265 4201 4118 4041 3927 
>5.0% 4623 4485 4303 4103 3867 3626 
 
Year 0 1 2 3 4 5 
5-year 
predicted risk 
Persons at risk by year 
<2.5% 1817 1808 1798 1777 1751 1729 
2.5-5% 748 732 707 691 675 651 
>5.0% 524 501 484 454 433 396 
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SUPPLEMENTAL MATERIAL 
Online methods 
AF ascertainment 
AGES 
Atrial fibrillation or atrial flutter was diagnosed from Minnesota-coded ECGs recorded at AGES study 
exams and from ICD-9 427.3 or ICD-10 I48 codes from hospital discharges in the National Hospital of 
Iceland database through April 2010.  
ARIC 
AF in ARIC was identified from 3 sources: ECG conducted at each study visit, hospital discharge codes 
(ICD-9CM 427.31, AF, or 427.32, atrial flutter), and death certificates (ICD-9 427.3 or ICD-10 I48). AF 
cases occurring during the same hospitalization as open cardiac surgery were not included as events.1, 2 
CHS 
Incidence of AF and atrial flutter in CHS was identified from standard 12-lead electrocardiograms 
performed at each study visit, and from hospitalization discharge codes (ICD-9CM 427.31 or 427.32). 
Data from hospitalizations have been obtained through biannual contact with study participants and 
from information obtained from the Centers for Medicare and Medicaid Services.3 
FHS 
Participants were classified as having AF if atrial fibrillation or atrial flutter was present on an ECG 
derived from a Framingham Study clinic tracing, on an ECG during an encounter with an external 
clinician, or by Holter monitoring, or if it was noted in hospital records. All incident AF cases were 
reviewed and adjudicated by one of two Framingham cardiologists.4 
RS 
AF cases were ascertained at baseline and during follow-up as described previously.5 Briefly, ECGs were 
recorded and stored digitally, and analyzed by the Modular ECG Analysis System. Two research 
physicians and a cardiologist verified AF diagnoses. Additional information was obtained from general 
practitioner records, from outpatient clinics, and from a national database of hospitalizations, which 
records all hospitalization discharge diagnoses occurring in the Netherlands. AF cases occurring during a 
serious disease resulting in death, or during myocardial infarction or cardiac operative procedures who 
recovered during the hospital admission were not included. 
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Assessment of covariates 
AGES 
Standard examination protocols and questionnaires were completed in the AGES study. Clinic visits 
included anthropometry, blood pressure measurement (defined as the mean value of two consecutive 
blood pressure measurements), electrocardiogram, and measures of different physical and cognitive 
function domains. Blood samples were drawn after overnight fasting. Total cholesterol, high-density 
lipoprotein (HDL) cholesterol, triglycerides, and glucose were analyzed on a Hitachi 912, using reagents 
from Roche Diagnostics and following the manufacturer's instructions. Low-density lipoprotein (LDL) 
was calculated using the Friedewald equation. Diabetes was defined from a self-report of a physician 
diagnosis, use of oral hypoglycemic agents or insulin, or a fasting blood glucose ≥126 mg/dL. Diagnoses 
of myocardial infarction and heart failure were based on hospital discharge records. 
ARIC 
Study participants were asked to fast for 12 hours before the clinic visit, during which a blood sample 
was obtained and a physical examination performed.  Race, smoking status, and drinking status were 
determined by participant self-report. Blood collection and processing techniques for the ARIC study 
have been previously described.6 Enzymatic methods were used to measure total cholesterol and 
triglycerides. High-density lipoprotein cholesterol was measured enzymatically after dextran sulfate-
Mg2+ precipitation of other lipoproteins. Low-density lipoprotein cholesterol levels were estimated using 
the Friedewald formula for subjects with triglycerides levels <400 mg/dl.  Standing height and waist 
circumference (at the level of the umbilicus) were measured to the nearest centimeter in a scrub suit 
and without shoes. Body mass index was calculated as weight (in kilograms) divided by height (in 
meters) squared. Blood pressure was measured 3 times with the subject in the sitting position after 5 
minutes of rest using a random-zero sphygmomanometer, and the last 2 measurements were averaged. 
Participants were asked to bring all medications with them to the clinic visits. A prescription bottle or 
self-report was used to determine cholesterol and blood pressure medication use. A 12-lead ECG at rest 
was used to define the PR interval and the presence of left ventricular hypertrophy (LVH). ECG-
diagnosed LVH was considered present if the Cornell voltage was >28 mm in men or >22 mm in women. 
A participant was categorized as having diabetes if she or he had a fasting glucose of ≥126 mg/dl or 
nonfasting glucose level of ≥200 mg/dl, reported a physician diagnosis of diabetes, or was currently 
taking medication for diabetes. Prevalent coronary heart disease at baseline included a history of 
myocardial infarction, myocardial infarction adjudicated from the baseline ECG, or a history of coronary 
bypass or angioplasty. Prevalent heart failure was defined as a previous hospitalization for heart failure. 
Presence of cardiac murmur was assessed in the baseline examination but not in following visits. 
CHS 
Participants had annual examinations including assessment of cardiovascular risk factors, prior 
cardiovascular diseases, medications, height, weight, seated blood pressure, and a 12-lead 
electrocardiogram through 1999. Racial identity was provided by self-report. A history of heart failure at 
baseline was defined by signs, symptoms, clinical tests, physician diagnosis, and/or medical therapy. 
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Prevalent coronary heart disease was defined by a history of myocardial infarction or angina pectoris 
confirmed by retrospective review of hospitalization medical records, or self-report of coronary 
angioplasty. Diabetes was defined as use of oral hypoglycemic agents or insulin, or a fasting blood 
glucose ≥126 mg/dl. ECG-LVH was defined according to Cornell voltage. 
FHS 
Cardiovascular disease risk factors were defined as follows: diabetes was diagnosed as fasting glucose 
≥126 mg/dL, or use of hypoglycemic medications; the average of two Framingham Study physician 
systolic and diastolic blood pressure measurements in mm Hg with the participant seated. Medication, 
alcohol use and smoking were ascertained by self-report. Current smoking was defined as regular use of 
one or more cigarettes/day within the year prior to the Framingham clinic visit. Glucose and lipids were 
measured after an overnight fast in the Framingham Study laboratory. Cardiovascular events were 
adjudicated by a panel of 3 physicians, examining participant hospitalization and outpatient records. 
Heart failure was diagnosed based on major and minor clinical criteria that have been used for all heart 
failure cases of Framingham Heart Study participants. Myocardial infarction was diagnosed based on the 
presence of clinical history, electrocardiographic signs, and biomarkers. ECG-based left ventricular 
hypertrophy was considered present when a participant had voltage criteria for left ventricular 
hypertrophy with lateral repolarization changes.7 
RS 
Information on current health status, medical history, and smoking was obtained using a computerized 
questionnaire. Participants were classified as current or non-smokers. Body mass index (BMI) was 
calculated as weight in kilograms divided by the square of height in meters. Blood pressure was 
measured twice at the right upper arm with a random zero mercury sphygmomanometer in the sitting 
position. Systolic and diastolic blood pressures were calculated as the average of the two consecutive 
measurements. A history of myocardial infarction was defined as a self-reported myocardial infarction 
with hospital admission or the presence of a myocardial infarction on the ECG. Left ventricular 
hypertrophy was diagnosed by the MEANS program using the Sokolow-Lyon cut-off of ≥3500 V. 
Diabetes was defined as the use of anti-diabetic medication or a random or post-load serum glucose 
level of 200 mg/dL or more. Diagnosis of heart failure was based on a score of heart failure symptoms, 
on medication prescribed with the indication of heart failure, on hospital discharge diagnoses, and on 
the information available in general practitioner files. Blood samples were drawn by venipuncture, and 
serum total cholesterol and HDL cholesterol were measured with an automated enzymatic method. 
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eTable 1. Number of participants excluded by cohort applying exclusion criteria sequentially 
 ARIC CHS FHS AGES RS 
Initial sample 11656 5353 3113 5427* 4215 
Prevalent AF 521 150 PE 527 282 
Age <46 or >94, years 0 7 275 5 21 
Creatinine ≥2 mg/dL 48 84 PE 55 8 
Not white or African-American 30 32 0 0 62 
Missing variables 382 37 PE 371 639 
Eligible sample 10675 5043 2838 4469 3203 
PE: Previously excluded from study sample 
 
* There are 5764 participants in the AGES cohort, but only 5427 came to the study center. Other 
participants received a home-visit or provided blood samples only and, therefore, were excluded from 
this analysis. 
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eTable 2. Reclassification among individuals who developed AF and who did not develop AF during a 5-
year follow-up using the augmented score (which includes ECG measurements). Net reclassification 
improvement (NRI), -0.0032; 95% CI, -0.0178 to 0.0113. 
 
Participants who developed AF 
Augmented score 
Simple score <2.5% 2.5-5% >5% Total 
<2.5% 97 6 1 104 
2.5-5% 4 161 5 171 
>5% 0 16 517 532 
Total 101 183 523 807 
Participants who did not develop AF 
Augmented score 
Simple score <2.5% 2.5-5% >5% Total 
<2.5% 8109 151 0 8260 
2.5-5% 192 4499 184 4875 
>5% 0 248 4366 4614 
Total 8301 4898 4550 17749 
Data are number of participants. Green cells correspond to desirable reclassification, while red cells 
correspond to undesirable reclassification. 
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eTable 3. Model discrimination and calibration separately in each derivation cohort 
 ARIC CHS FHS 
N 10675 5042 2831 
CHARGE AF simple score 
C-statistic (95% CI)  0.71 (0.68, 0.74)  0.70 (0.68, 0.73)  0.78 (0.74, 0.83) 
Calibration chi-square (p-value)  6.6 (0.67)  17.3 (0.045)  14.2 (0.11) 
Discrimination slope 0.017 0.054  0.057 
CHARGE AF augmented score 
C-statistic (95% CI)  0.72 (0.68, 0.75) 0.71 (0.68, 0.73)   0.78 (0.74, 0.83) 
Calibration chi-square (p-value) 5.1 (0.82) 11.1 (0.27)   8.0 (0.54) 
Discrimination slope 0.018  0.058 0.060 
FHS AF score 
C-statistic (95% CI)  0.67 (0.64, 0.71) 0.66 (0.64, 0.69)   0.78 (0.74, 0.82) 
Calibration chi-square, p-value  32.2 (0.0002)  279.8 (<0.0001)  45.1 (<0.0001) 
Discrimination slope  0.013  0.046  0.049 
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eTable 4. Variables included in the CHARGE-AF simple model and previously published risk models for 
the prediction of AF 
CHARGE-AF FHS risk score8 ARIC risk score9 
age age age 
 sex  
race  race 
height  height 
weight body mass index  
systolic BP systolic BP systolic BP 
diastolic BP   
smoking  smoking 
antihypertensive medication antihypertensive medication antihypertensive medication 
diabetes   
myocardial infarction  coronary heart disease 
heart failure heart failure heart failure 
 cardiac murmur cardiac murmur 
 PR interval  
  ECG-derived LVH 
  ECG-derived LAE 
BP: blood pressure; ECG: electrocardiogram; LAE: left atrial enlargement; LVH: left ventricular 
hypertrophy 
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eFigure 1. Observed cumulative risk of AF by categories of predicted risk according to CHARGE AF simple 
score in whites and African Americans. Green line: >5%, red line: 2.5-5%, blue line: <2.5%
 
Year 0 1 2 3 4 5 
5-year 
predicted risk 
Persons at risk by year 
<2.5% 6547 6516 6489 6440 6379 6305 
2.5-5% 4297 4265 4201 4118 4041 3927 
>5.0% 4623 4485 4303 4103 3867 3626 
 
Year 0 1 2 3 4 5 
5-year 
predicted risk 
Persons at risk by year 
<2.5% 1817 1808 1798 1777 1751 1729 
2.5-5% 748 732 707 691 675 651 
>5.0% 524 501 484 454 433 396 
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